1-4 of 4
Gaspar J. Kitange
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier

Minjee Kim, Daniel J. Ma, David Calligaris, Shuangling Zhang, Ryan W. Feathers, Rachael A. Vaubel, Isabelle Meaux, Ann C. Mladek, Karen E. Parrish, Fang Jin, Cedric Barriere, Laurent Debussche, James Watters, Shulan Tian, Paul A Decker, Jeanette E. Eckel-Passow, Gaspar J. Kitange, Aaron J. Johnson, Ian F. Parney, Panos Z. Anastasiadis, Nathalie Y.R. Agar, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (9): 1893–1901.
https://doi.org/10.1158/1535-7163.MCT-17-0600
Published: 04 September 2018
View article titled, Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier
Open the PDF for Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood–Brain Barrier in another window
Includes: Supplementary data
Journal Articles

Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma

Sani H. Kizilbash, Shiv K. Gupta, Kenneth Chang, Ryo Kawashima, Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2735–2746.
https://doi.org/10.1158/1535-7163.MCT-17-0365
Published: 03 December 2017
View article titled, Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma
Open the PDF for Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.

Ryan S. Youland, Gaspar J. Kitange, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B68.
https://doi.org/10.1158/1535-7163.TARG-11-B68
Published: 12 November 2011
View article titled, Abstract B68: Differential gene expression associated with temozolomide resistance development in glioblastoma xenografts.
Journal Articles

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel

Jann N. Sarkaria, Lin Yang, Patrick T. Grogan, Gaspar J. Kitange, Brett L. Carlson, Mark A. Schroeder, Evanthia Galanis, Caterina Giannini, Wenting Wu, Eduard B. Dinca, C. David James
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 1167–1174.
https://doi.org/10.1158/1535-7163.MCT-06-0691
Published: 15 March 2007
View article titled, Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel
Open the PDF for Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel in another window